Option chain shows key data for Green Thumb Industries's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Green Thumb Industries.

Green Thumb Industries (OTC:GTBIF) Stock, Option Chain

Green Thumb Industries

Green Thumb Industries is headquartered in Chicago, Illinois, and produces and sells medicinal and recreational cannabis through wholesale and retail channels in the United States. It has a presence in 14 states and operates 97 cannabis stores under the brand Rise. GTI is focusing its expansion on limited license states with large populations, and it does not currently export into the global medical market due to US federal prohibition. It offers multiple products under a portfolio of cannabis consumer packaged goods brands, including &Shine, Beboe, Dogwalkers, Doctor Solomon's, Good Green, incredibles, and RYTHM.

AI-Generated Image

Cannabis

Market Summary

News

Retail Sales

Success Stories

Startups

Small Business

Markets

General

GTBIF

Millennials dominate the pre-roll market, accounting for 44.6% of purchases in September 2024, totaling $103.9 million. 

Pre-Rolls, The Avocado Toast Of Cannabis: Why Millennials Are Spending +$100M A Month

Analyst Color

Macro Economic Events

Mid Cap

Economics

Exclusives

Analyst Ratings

Trading Ideas

THE CANNABIST CO HLDG by THE CANNABIST COMPANY HOLDINGS INC.

CBSTF

CRLBF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

GRAM

VRNOF

The post-election landscape raises uncertainty for cannabis MSOs, with investors hoping for potential relief from the new administration.

Can Trump&#39;s Return Save The Cannabis Sector? Debt Mounts As Giants Face Post-Election Reckoning

jan-zwarthoed-24C4MlZRqeI-unsplash

Entrepreneurship

CSE:GTII

CSE:TRUL

GTII

HITI

TCNNF

TRUL

TSX:CURA

TSXV:HITI

RISE Dispensaries, a cannabis retail chain owned by Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), opened RISE Dispensary Orlando on Good Homes Road on Friday, Nov. 8. Located at 725 Good Homes Road, the new West Orlando location expanded RISE Dispensaries&#39; retail footprint in Florida to 21 locations and 99 nationwide. Cannabis giant Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) opened a new medical dispensary in Miami, Florida in October. Curaleaf Miami Bird Road, located at 8868 SW Bird Rd. in Miami, brought the company&#39;s Florida store count to 66 locations, with 151 dispensaries total nationwide.Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF), one of the biggest supporters of Amendment 3 which was rejected by Florida voters earlier this month and would have legalized recreational cannabis in the Sunshine State, additionally expanded its already substantial retail footprint statewide.

Medical Marijuana Footprint Grows In Florida As Legalization Push Fizzles, And Other New Cannabis Stores

GREEN THUMB INDUS SUB VTG by Green Thumb Industries Inc.

Green Thumb Industries Inc

Needham analyst Mike Cikos maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $160 to $200.

Price Target

SNOW

Needham Maintains Buy on Snowflake, Raises Price Target to $200

<ul>
<li>Aphexda is Biolinerx's FDA-Approved Stem Cell Mobilization Agent Indicated In Combination With Filgrastim For Collection And Subsequent Autologous Transplantation In Patients With Multiple Myeloma.</li>
<li>BioLineRx to receive $10 million upfront payment from Ayrmid Ltd. (parent company of Gamida Cell) plus up to $87 million in commercial milestones, as well as royalties on net sales ranging from 18% to 23%.</li>
<li>BioLineRx retains rights to develop and commercialize motixafortide in solid tumors, including PDAC.</li>
<li>BioLineRx received $9 million equity investment from certain funds managed by Highbridge Capital Management, LLC to support company's pipeline and expansion.</li>
<li>Transactions enable significant reduction in BioLineRx's operational expenses and debt, and allow the company to focus on development activities in areas of high unmet need in oncology and rare diseases –</li>
</ul>

Biotech

Health Care

Contracts

BLRX

BioLineRx And Ayrmid Entered Into A License Agreement For Motixafortide (Commercially Sold In The US As Aphexda), BioLineRx Will Receive A $10M Upfront Payment And Is Also Eligible To Receive Up To An Additional $87M Of Potential Commercial Milestones, Plus Royalties Between 18%-23% On Net Sales Of Aphexda

Trimble will provide fleet management and telematics solutions to vehicles across PFG's three business segments including Performance Foodservice Core-Mark and Vistar.&nbsp;
All PFG vehicles will be equipped with Trimble Instinct, Trimble's in-cab ecosystem that seamlessly connects drivers and back-office staff to boost safety, compliance and efficiency.
 &nbsp;

PFGC

TRMB

Performance Food Group Selects Trimble As Its Premier Fleet Management Provider; Migrates 100% Of Its Fleet Management Business To Trimble Instinct, Doubling Trimble-Serviced Trucks To Over 8,000

Earnings

Citigourp Global Markets 2% Protected Notes Linked To The Djia

PDD Holdings Q3 Adj EPADS $2.65 Misses $2.82 Estimate, Sales $14.16B Miss $14.47B Estimate

Artificial intelligence (AI) darling Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) <a href="https://www.benzinga.com/news/earnings/24/11/42099904/nvidia-beats-q3-revenue-eps-estimates-supply-constraints-ding-stock-huang-says-age-of-ai-is-in-full-steam">beat expectations yet again</a> with impressive third-quarter revenue and earnings reported after Wednesday's market close. 
What happened: The world's most valuable company <a href="https://www.benzinga.com/24/11/42099904/nvidia-q3-earnings-highlights">disclosed </a>third-quarter revenue of $35.1 billion and earnings per share of 81 cents, both beating analysts' estimates.&nbsp;
The Jensen Huang-led firm has had a blockbuster run on equity markets in the last few years, multiplying investors' money by orders of magnitude.&nbsp;
Indeed, Nvidia shares have exploded by 2,718% in the last five years, outperforming all well-known companies on Wall Street.
In comparison, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>)—the world's most valued cryptocurrency exerting a similar influence on the digital assets market—grew 1,171% over the last five years.
See Also: <a href="https://www.benzinga.com/24/11/42079799/microstrategys-michael-saylor-to-advocate-for-bitcoin-investment-at-microsoft-board-meeting-offers-to-educate-rumble-ceo-with-the-strategy">Microstrategy&#8217;s Michael Saylor To Advocate For Bitcoin At Microsoft Board Meeting, Offers To Educate Rumble CEO As Well</a>
<h2 class="wp-block-heading">Which Is Offering Better Returns Relative To Risk?</h2>
Both Nvidia and Bitcoin are risk-laden investments, and traders must navigate their inherent volatility to profit.
To get a more accurate picture, analysts track the Sharpe Ratio, a measure of risk-adjusted returns. 
For Bitcoin, this ratio stood at -5 as of this writing, <a href="https://in.tradingview.com/chart/XlzxagWe/?symbol=BITSTAMP%3ABTCUSD">per </a>TradingView, implying that the expected return was lower than that of a risk-free investment, such as a Treasury yield.&nbsp;
On the other hand, Nvidia <a href="https://www.tradingview.com/chart/XlzxagWe/?symbol=NASDAQ%3ANVDA">showed </a>a Sharpe ratio of 0.69, indicating that investment in the stock was generating positive returns above the risk-free rate.
<h2 class="wp-block-heading">Are Their Valuations Inflated?</h2>
Another metric to compare the two hot financial assets was whether they were expensive or cheap relative to their fundamentals.
For stocks, this is typically measured by the price-to-earnings ratio, or simply the P/E ratio.&nbsp;
Nvidia's P/E ratio showed a reading of 73.478 per TradingView, suggesting that the stock was highly overpriced. It could also imply that investors expect the company to have stronger performance and higher earnings in the future.
The P/E counterpart for Bitcoin is the network value to transactions ratio or NVT ratio.
According to on-chain analytics firm <a href="https://cryptoquant.com/asset/btc/chart/network-indicator/nvt-ratio?window=DAY&amp;sma=0&amp;ema=0_30&amp;priceScale=log&amp;metricScale=log&amp;chartStyle=column">CryptoQuant</a>, the 30-day EMA of Bitcoin's NVT was at 28.28 at the time of writing, a decline from 36.32 recorded at the beginning of the month.
The decline implied that transaction volume was outperforming market growth or that valuation had dropped without any change in transaction activity.
Price Action: At the time of writing, Bitcoin was trading at $97,396.60, rising 4.97% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. Shares of Nvidia were down 2.49% in after-hours trading.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42079984/dogecoin-bitcoin-left-in-the-dust-by-ai-meme-coin-goat-as-nvidias-q3-earnings-draw-near">Dogecoin, Bitcoin Left In The Dust By AI Meme Coin GOAT As Nvidia&#8217;s Q3 Earnings Draw Near</a></li>
</ul>
Photos courtesy: Nvidia and Pixabay

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Tech

$BTC

NVDA

Nvidia Vs. Bitcoin: Jensen Huang-Led Chip Giant's Stock Outperformed The Top Cryptocurrency Over 5 Years. Here's How They Compare On Other Metrics

Benchmark analyst Cody Acree maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $170 to $190.

Benchmark Maintains Buy on NVIDIA, Raises Price Target to $190

Roth MKM analyst Joe Reagor initiates coverage on Stardust Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) with a Buy rating and announces Price Target of $13.

Initiation

SDST

Roth MKM Initiates Coverage On Stardust Power with Buy Rating, Announces Price Target of $13

Morgan Stanley analyst James Faucette upgrades Evertec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVTC#NYSE">EVTC</a>) from Underweight to Equal-Weight and raises the price target from $33 to $35.

Upgrades

EVTC

Morgan Stanley Upgrades Evertec to Equal-Weight, Raises Price Target to $35

Morgan Stanley analyst Brian Wilczynski initiates coverage on UMB Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UMBF#NASDAQ">UMBF</a>) with a Overweight rating and announces Price Target of $156.

UMBF

Morgan Stanley Initiates Coverage On UMB Financial with Overweight Rating, Announces Price Target of $156

Needham analyst Quinn Bolton maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Buy and raises the price target from $145 to $160.

Needham Maintains Buy on NVIDIA, Raises Price Target to $160

Morgan Stanley analyst Judah Frommer initiates coverage on 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Underweight rating and announces Price Target of $8.

FDMT

Morgan Stanley Initiates Coverage On 4D Molecular Therapeutics with Underweight Rating, Announces Price Target of $8

Morgan Stanley analyst Judah Frommer initiates coverage on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) with a Equal-Weight rating and announces Price Target of $31.

APLS

Morgan Stanley Initiates Coverage On Apellis Pharmaceuticals with Equal-Weight Rating, Announces Price Target of $31

Quantum-Si Provides Update On Innovation Roadmap & New Development Partnerships; Announces Next-Generation Platinum System, The Platinum Pro, Scheduled To Launch In H1 Of 2025

Guidance

SCVL

Shoe Carnival Lowers FY24 Net Sales Outlook: Sees Revenues Of $1.20B-$1.23B Vs $1.23B Estimate (Prior View:  $1.23B-$1.25B); Company Reiterates FY24 Adjusted EPS Outlook Of $2.60-$2.75 Vs. $2.63 Estimate

With more than a week of deals planned across the entire assortment, Target will offer some of its lowest prices of the season on thousands of items, including up to 50% off tech, apparel, video games, board games, small appliances, luggage, holiday trees and other must-have items for gifting and gathering.

Target Reveals Its Lineup Of Black Friday Deals Available Now Through Nov. 30 Online And In Its Stores

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) with a Buy and raises the price target from $4 to $5.5.

HC Wainwright & Co. Maintains Buy on Quantum-Si, Raises Price Target to $5.5

This collaboration aims to accelerate the development of advanced ceramic-based microspheres, a groundbreaking advancement in radiotherapeutic applications.
The partnership will see SINTX leverage its expertise in ceramic manufacturing to support NED medical's pre-clinical testing needs and perform the necessary process validation and verification activities to transition the microsphere process from the R&amp;D scale to pilot production.

SINT

SINTX  Signs Joint Development Agreement With NED Medical To Develop Next Generation Radiotherapeutic Solutions That May Have Transformative Impact On Cancer Treatment

Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) reported quarterly earnings of $0.71 per share which beat the analyst consensus estimate of $0.67 by 5.97 percent. The company reported quarterly sales of $306.885 million which missed the analyst consensus estimate of $316.950 million by 3.18 percent. This is a 4.07 percent decrease over sales of $319.914 million the same period last year.

Earnings Beats

Earnings Misses

Shoe Carnival Q3 2024 Adj. EPS $0.71 Beats $0.67 Estimate, Sales $306.885M Miss $316.950M Estimate

GEHC

GE HealthCare Sets Medium-Term 2026-2028 Targets: Organic Revenue Growth Mid-Single Digit (4% - 6%), Adjusted EPS Growth High-Single Digit To Low-Double Digit

Keefe, Bruyette &amp; Woods analyst Damon Delmonte initiates coverage on Northeast Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBN#NASDAQ">NBN</a>) with a Market Perform rating and announces Price Target of $102.

Keefe, Bruyette & Woods Initiates Coverage On Northeast Bank with Market Perform Rating, Announces Price Target of $102

Here are the major earnings after the close today

In this edition of "Rising High," The Fly conducted an exclusive interview with Adam Wilks, Co-Founder and CEO of Carma HoldCo, a house of brands f...

Rising High: Exclusive talk with house of brands Carma HoldCo

Green Thumb Industries&nbsp; GAAP EPS of $0.04 misses by $0.02, revenue of $287M beats by $4.06M

Green Thumb Industries, Inc. (GTBIF) Q3 2024 Earnings Call Transcript

Green Thumb's Q3 financial metrics were poor across the board.

Green Thumb Q3 Results Show 58% Decline In Net Income And 5% Decline In EBITDA

In a report released today, Mike Hickey from Benchmark Co. maintained a Buy rating on Green Thumb Industries (GTBIF – Research Report), with a pric...

Benchmark Co. Sticks to Its Buy Rating for Green Thumb Industries (GTBIF)

Haywood analyst Neal Gilmer maintained a Buy rating on Green Thumb Industries (GTBIF – Research Report) today and set a price target of C$24.00. Th...

Haywood Sticks to Their Buy Rating for Green Thumb Industries (GTBIF)

In a report released today, Neal Gilmer from Haywood maintained a Buy rating on Green Thumb Industries (GTBIF – Research Report), with a price targ...

Haywood Remains a Buy on Green Thumb Industries (GTBIF)

Weed stocks spike after report on Trump support for marijuana reforms

Cannabis stocks gain as Trump picks pro-marijuana Congressman Gaetz for AG post

AAOI

AAON

AAWH

ACHR

ACHV

ACRHF

ADMA

ADPT

AEYE

AFRM

AKAM

ALLO

ALRM

ALTM

AMPL

AMRC

ANET

ARCT

ARLO

ARRY

ASLE

ATAI

AYRWF

CANN

CMPS

CNBS

CRON

CVSI

DOCS

DVAX

FIVN

FNKO

FOSL

GSBD

HASI

HEAR

INDI

INGN

JUSHF

MSOS

NWSA

OPEN

OUST

PACB

PARA

PBPB

PBYI

PHUN

PINS

PLNH

PODD

PRCH

PTCT

PTMN

QDEL

RCEL

RCMT

RDFN

REZI

RIGL

RIVN

RLMD

SAND

SEMR

SENS

SIGA

TLRY

TSNDF

VREOF

YOLO

Press Releases

Green Thumb Industries Reports Second Quarter 2024 Results

Green Thumb Opens Its 20th Florida Location, RISE Dispensary Jacksonville, on September 13

Financing

Green Thumb Industries Refinances its Senior Debt Via Syndicated Credit Facility

Comments

Green Thumb Industries

Green Thumb Industries (GTBIF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga